Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study
Abstract Introduction Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets. Objectives This...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-01-01
|
| Series: | Dermatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s13555-024-01331-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832571979393138688 |
|---|---|
| author | Federico Diotallevi Giulia Matacchione Anna Campanati Elena Marinelli Busilacchi Nadia Viola Ilaria Pace Beatrice Fontana Roberta Roncarati Massimiliano Bonafè Manuela Ferracin Jacopo Sabbatinelli Fabiola Olivieri |
| author_facet | Federico Diotallevi Giulia Matacchione Anna Campanati Elena Marinelli Busilacchi Nadia Viola Ilaria Pace Beatrice Fontana Roberta Roncarati Massimiliano Bonafè Manuela Ferracin Jacopo Sabbatinelli Fabiola Olivieri |
| author_sort | Federico Diotallevi |
| collection | DOAJ |
| description | Abstract Introduction Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets. Objectives This study aimed to investigate changes in circulating miRNAs in psoriasis patients undergoing risankizumab therapy, an anti-IL-23 monoclonal antibody, to understand its impact on disease pathogenesis and treatment response. Methods Plasma samples from 12 psoriasis patients were collected before (T0) and after 1 year (T1) of risankizumab treatment and analyzed using small RNA sequencing. Findings were validated in a separate cohort of 23 patients using quantitative real-time PCR (qRT-PCR). T-regulatory cell (Treg) numbers and pro-inflammatory cytokine levels were also assessed. Results Significant clinical improvement was observed in all patients after 1 year of treatment, accompanied by increased Treg counts and reduced levels of pro-inflammatory cytokines. Twenty-four miRNAs exhibited differential expression post-treatment; 9 were downregulated and 15 upregulated. Notably, miR-200a-3p showed a significant correlation with baseline Psoriasis Area Severity Index (PASI), indicating its potential as a severity marker. Risankizumab therapy also decreased peripheral blood levels of IL-23, IL-1β, and IL-8. Conclusions This study identifies specific circulating miRNAs, including miR-200a-3p, as potential biomarkers for monitoring treatment responses in psoriasis patients. The findings underscore the therapeutic efficacy of risankizumab in modulating miRNA profiles and immune pathways associated with psoriasis pathogenesis. Overall, these results provide new insights into the mechanisms of risankizumab action and highlight miRNAs as promising candidates for personalized medicine approaches in psoriasis management. |
| format | Article |
| id | doaj-art-11e3a69a9ccc4ad886081f7cf2537023 |
| institution | Kabale University |
| issn | 2193-8210 2190-9172 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Dermatology and Therapy |
| spelling | doaj-art-11e3a69a9ccc4ad886081f7cf25370232025-02-02T12:09:38ZengAdis, Springer HealthcareDermatology and Therapy2193-82102190-91722025-01-0115112514010.1007/s13555-024-01331-9Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort StudyFederico Diotallevi0Giulia Matacchione1Anna Campanati2Elena Marinelli Busilacchi3Nadia Viola4Ilaria Pace5Beatrice Fontana6Roberta Roncarati7Massimiliano Bonafè8Manuela Ferracin9Jacopo Sabbatinelli10Fabiola Olivieri11Dermatological Clinic, Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle MarcheClinic of Laboratory and Precision Medicine, IRCCS INRCADermatological Clinic, Department of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle MarcheDepartment of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle MarcheClinical Immunology Service, Azienda Ospedaliero-Universitaria delle MarcheDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di BolognaDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di BolognaDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di BolognaDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di BolognaDepartment of Medical and Surgical Sciences (DIMEC), Alma Mater Studiorum - Università di BolognaClinic of Laboratory and Precision Medicine, IRCCS INRCADepartment of Clinical and Molecular Sciences (DISCLIMO), Università Politecnica delle MarcheAbstract Introduction Psoriasis is characterized by aberrant keratinocyte activity and immune cell infiltration, driven by immune-mediated pathways. MicroRNAs (miRNAs) play crucial roles in regulating these processes, offering insights into disease mechanisms and therapeutic targets. Objectives This study aimed to investigate changes in circulating miRNAs in psoriasis patients undergoing risankizumab therapy, an anti-IL-23 monoclonal antibody, to understand its impact on disease pathogenesis and treatment response. Methods Plasma samples from 12 psoriasis patients were collected before (T0) and after 1 year (T1) of risankizumab treatment and analyzed using small RNA sequencing. Findings were validated in a separate cohort of 23 patients using quantitative real-time PCR (qRT-PCR). T-regulatory cell (Treg) numbers and pro-inflammatory cytokine levels were also assessed. Results Significant clinical improvement was observed in all patients after 1 year of treatment, accompanied by increased Treg counts and reduced levels of pro-inflammatory cytokines. Twenty-four miRNAs exhibited differential expression post-treatment; 9 were downregulated and 15 upregulated. Notably, miR-200a-3p showed a significant correlation with baseline Psoriasis Area Severity Index (PASI), indicating its potential as a severity marker. Risankizumab therapy also decreased peripheral blood levels of IL-23, IL-1β, and IL-8. Conclusions This study identifies specific circulating miRNAs, including miR-200a-3p, as potential biomarkers for monitoring treatment responses in psoriasis patients. The findings underscore the therapeutic efficacy of risankizumab in modulating miRNA profiles and immune pathways associated with psoriasis pathogenesis. Overall, these results provide new insights into the mechanisms of risankizumab action and highlight miRNAs as promising candidates for personalized medicine approaches in psoriasis management.https://doi.org/10.1007/s13555-024-01331-9PsoriasisImmunomodulatory therapiesImmunodermatologymiRNAs |
| spellingShingle | Federico Diotallevi Giulia Matacchione Anna Campanati Elena Marinelli Busilacchi Nadia Viola Ilaria Pace Beatrice Fontana Roberta Roncarati Massimiliano Bonafè Manuela Ferracin Jacopo Sabbatinelli Fabiola Olivieri Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study Dermatology and Therapy Psoriasis Immunomodulatory therapies Immunodermatology miRNAs |
| title | Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study |
| title_full | Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study |
| title_fullStr | Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study |
| title_full_unstemmed | Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study |
| title_short | Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study |
| title_sort | circulating micrornas in patients with psoriasis treated with anti il 23 a cohort study |
| topic | Psoriasis Immunomodulatory therapies Immunodermatology miRNAs |
| url | https://doi.org/10.1007/s13555-024-01331-9 |
| work_keys_str_mv | AT federicodiotallevi circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT giuliamatacchione circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT annacampanati circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT elenamarinellibusilacchi circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT nadiaviola circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT ilariapace circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT beatricefontana circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT robertaroncarati circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT massimilianobonafe circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT manuelaferracin circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT jacoposabbatinelli circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy AT fabiolaolivieri circulatingmicrornasinpatientswithpsoriasistreatedwithantiil23acohortstudy |